The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
968
February 16, 1996
View Complete Issue         Table of Contents 2019 
Epoprostenol for Primary Pulmonary Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Epoprostenol for Primary Pulmonary Hypertension
February 16, 1996 (Issue: 968)
Epoprostenol sodium (Flolan - Glaxo Wellcome), also known as prostacyclin, has been approved by the US Food and Drug Administration for continuous intravenous treatment of primary pulmonary hypertension.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Epoprostenol for Primary Pulmonary Hypertension
Article code: 968b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.